Zikani Therapeutics Inc.
www.zikani.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zikani Therapeutics Inc.
With Sickle Cell Results For Pyrukynd, Agios Enters Increasingly Competitive Market
The company has significantly built up its pipeline since divesting its oncology business to Servier, with multiple Phase III readouts for Pyrukynd expected in 2024-2025.
Medtech 100: Big Three Companies Lead From The Front With Medtech Back On Solid Growth Footing
Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.
Big Three Lead From The Front With Medtech Back On Solid Growth Footing
Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.
Agios Anticipates PK Deficiency Diagnosis Ramp-Up After Pyrukynd Approval
The company hopes to grow the current diagnostic rate from 30% to 70% over two to five years. “Optimal reimbursement” for mitapivat will likely take a year, with Medicare/Medicaid lagging.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Eloxx Pharmaceuticals, Inc.
- Macrolide Pharmaceuticals Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice